Aardvark Therapeutics shareholders face Oct. 13 deadline in securities suit notice
The Law Offices of Frank R. Cruz says shareholders who bought Aardvark Therapeutics stock during the class period may contact the firm ahead of an Oct. 13, 2026, lead plaintiff deadline.
The Law Offices of Frank R. Cruz says Aardvark Therapeutics, Inc. shareholders with losses may seek to participate in an ongoing securities fraud class action over claims tied to ARD-101.
The PR Newswire notice, dated Aug. 27, 2026, says the suit covers investors who bought Aardvark Therapeutics shares during a class period running from Feb. 10, 2025, through May 14, 2026. It says the lead plaintiff deadline is Oct. 13, 2026.
According to the release, the complaint alleges defendants made materially false and misleading statements and failed to disclose material adverse facts about the company’s business, operations and prospects. The notice also says the complaint alleges ARD-101 was less safe than investors had been led to believe and that its clinical, regulatory and commercial prospects were overstated.
The release says the statements at issue were materially false and misleading at all relevant times. It does not include a response from Aardvark Therapeutics.
The notice says investors with losses may contact the firm by email, phone or through its website. It says those who email should include a mailing address, telephone number and number of shares purchased. The release also says class members need not take action now and may retain counsel of their choice or remain absent members.
The announcement identifies the source as The Law Offices of Frank R. Cruz in Los Angeles and includes an attorney-advertising disclaimer.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()